Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer

Publication Name: European Journal of Cancer

Author(s): Valesca Retel, MA Joore, WH van Harten

Background: The 70-gene signature (MammaPrint) is a prognostic test used to guide adjuvant treatment decisions in patients with node-negative breast cancer. In order to decide upon its use, a systematic comparative analysis of the effects of the 70-gene signature,the Saint … Continued

Use of a genomic test (MammaPrint) in daily clinical practice to assist in risk stratification of young breast cancer patients

Publication Name: Archives of Gynecology and Obstetrics

Author(s): Georg Kunz

Purpose: Breast cancer as a heterogeneous disease demands reliable tools in order to identify those patients who most likely will benefit from receiving adjuvant treatment, such as chemotherapy. MATERIALS AND METHODS: The MammaPrint test was established on the basis of … Continued

The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer

Publication Name: Breast Cancer Research and Treatment

Author(s): Michael Knauer, Stella Mook, Emiel J. T. Rutgers, Richard A. Bender, Michael Hauptmann, Marc J. van de Vijver, Rutger H. T. Koornstra, Jolien M. Bueno-de-Mesquita, Sabine C. Linn, Laura J. van ’t Veer

Multigene assays have been developed and validated to determine the prognosis of breast cancer. In this study, we assessed the additional predictive value of the 70-gene MammaPrint signature for chemotherapy (CT) benefit in addition to endocrine therapy (ET) from pooled … Continued

MammaPrint 70-gene profile quantifies the likelihood of recurrence for early breast cancer.

Publication Name: Expert Opinion Medical Diagnostics

Author(s): Phillipe L Bedard, Stella Mook, Martine J Piccart-Gebhart, Emiel T Rutgers, Laura J van ‘t Veer and Fatima Cardoso

Background: Over the past few years, a variety of multigene expression profiles have been developed to improve prognostication for early stage breast cancer and reduce overtreatment with chemotherapy. MammaPrint is the only test cleared by the US Food and Drug … Continued

The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age.

Publication Name: Annals of Oncology

Author(s): Mook S, Schmidt MK, Weigelt B

Background: The majority of breast cancer patients are postmenopausal women who are increasingly being offered adjuvant chemotherapy. Since the beneficial effect of chemotherapy in postmenopausal patients predominantly occurs in the first 5 years after diagnosis, a prognostic marker for early … Continued

Validation of 70-gene prognosis signature in node-negative breast cancer

Publication Name: Breast Cancer Research & Treatment

Author(s): Bueno-de-Mesquita JM, Keijzer R, Linn SC

Purpose: The 70-gene prognosis signature (van’t Veer et al., Nature 415(6871):530–536, 2002) may improve the selection of lymph node-negative breast cancer patients for adjuvant systemic therapy. Optimal validation of prognostic classifiers is of great importance and we therefore wished to … Continued

Gene expression profiling in breast cancer – design of a pooled database to address open questions

Publication Name: European Surgery

Author(s): Michaël Knauer, Etienne Wenzl, Emiel J Rutgers, Sabine C Linn, Laura J van't Veer

BACKGROUND: The Netherlands Cancer Institute used DNA microarray analyses to identify a 70-gene expression profile strongly predictive of a short interval to distant metastases in breast cancer. For patients with small tumors, the signature is not yet adequately validated. Furthermore, … Continued

The 70-gene prognosis-profile predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study

Publication Name: Breast Cancer Research and Treatment

Author(s): Mook, S, Schmidt, M.S., Viale, G

Purpose: The 70-gene prognosis-signature has shown to be a valid prognostic tool in node-negative breast cancer. Although axillary lymph node status is considered to be one of the most important prognostic factors, still 25–30% of node-positive breast cancer patients will … Continued

Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial.

Publication Name: European Journal of Cancer

Author(s): S. Mook, H. Bonnefoi, G. Pruneric, D. Larsimont, J. Jaskiewicz, M.D. Sabadell, G. MacGrogan, L.J. van’t Veer, F. Cardoso, E.J. Rutgers.

Purpose: The 70-gene prognosis-signature is a prognostic tool for early breast cancer analysis. In addition to scientific evidence, implementation of the signature in clinical trials and daily practice requires logistical feasibility. The aim of our study was to test logistics … Continued

The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer.

Publication Name: Breast Cancer Research and Treatment

Author(s): Marieke E. Straver, Annuska M. Glas, Juliane Hannemann, Jelle Wesseling, Marc J. van de Vijver, Emiel J. Th. Rutgers, Marie-Jeanne T. F. D. Vrancken Peeters, Harm van Tinteren, Laura J. van‘t Veer, Sjoerd Rodenhuis

The 70-gene signature (MammaPrintTM) is a prognostic tool used to guide adjuvant treatment decisions. The aim of this study was to assess its value to predict chemosensitivity in the neoadjuvant setting. We obtained the 70-gene profile of stage II–III patients … Continued